Table 1.
Age at breast cancer diagnosis, y | |
51-64 | 462 (20.3) |
65-69 | 386 (17.0) |
70-74 | 580 (25.5) |
75-79 | 444 (19.5) |
80-99 | 400 (17.6) |
Year of breast cancer diagnosis | |
1994-1999 | 416 (18.3) |
2000-2004 | 744 (32.7) |
2005-2009 | 490 (21.6) |
2010-2014 | 416 (18.3) |
2015-2018 | 206 (9.1) |
Characteristics at enrollment in the Women’s Health Initiative | |
Race | |
American Indian/Alaska Native | 8 (0.4) |
Asian/Pacific Islander | 27 (1.2) |
Black/African American | 650 (28.6) |
White | 1475 (64.9) |
More than one race | 42 (1.8) |
Unknown/not reported | 70 (3.1) |
Hispanic/Latina ethnicity | |
No | 2033 (89.5) |
Yes | 234 (10.3) |
Unknown/not reported | 5 (0.2) |
Education | |
High school diploma/GED or less | 526 (23.2) |
School after high school | 934 (41.1) |
College degree or higher | 794 (34.9) |
Unknown | 18 (0.8) |
Family income | |
<$20,000 | 391 (17.2) |
$20,000-$49,999 | 1,063 (46.8) |
$50,000-$74,999 | 422 (18.6) |
≥$75,000 | 274 (12.1) |
Unknown | 122 (5.4) |
Family history of myocardial infarction or stroke | |
No | 730 (32.1) |
Yes | 1,477 (65.0) |
Unknown | 65 (2.9) |
Alcohol intake | |
Nondrinker/past drinker | 730 (32.1) |
<7 drinks per week | 1,273 (56.0) |
7+ drinks per week | 238 (10.5) |
Unknown | 31 (1.4) |
Antihypertensive use | |
ACE inhibitor/ARB use | 191 (8.4) |
Beta blocker use | 134 (5.9) |
Calcium channel blocker use | 253 (11.1) |
Diuretic use | 359 (15.8) |
Characteristics assessed before breast cancer diagnosisa | |
Ever smoked | |
No | 1,166 (51.3) |
Yes | 1,104 (48.6) |
Unknown | 2 (0.1) |
Body mass index, kg/m2 | |
<25 | 390 (17.2) |
25-<30 | 755 (33.2) |
≥30 | 1,124 (49.5) |
Unknown | 3 (0.1) |
Waist circumference ≥88 cm | |
No | 932 (41.0) |
Yes | 1,338 (58.9) |
Unknown | 2 (0.1) |
Waist-to-hip ratio >0.85 | |
No | 1,418 (62.4) |
Yes | 852 (37.5) |
Unknown | 2 (0.1) |
Leisure time physical activity, MET h/wk | |
0 | 490 (21.6) |
>0-<9.0 | 866 (38.1) |
≥9.0 | 872 (38.4) |
Unknown | 44 (1.9) |
History of statin use | 607 (26.7) |
History of nonsteroidal anti-inflammatory drug use | 1,265 (55.7) |
History of hypertensionb | 1,718 (75.6) |
History of treated diabetes | 422 (18.6) |
History of myocardial infarction | 76 (3.3) |
Tumor characteristics | |
Summary stage | |
Localized | 1,649 (72.6) |
Regional/distant | 587 (25.8) |
Unknown | 36 (1.6) |
Hormone receptor status | |
ER+/PR+ | 1,407 (61.9) |
ER−/PR− | 343 (15.1) |
Mixed | 362 (15.9) |
Unknown | 160 (7.0) |
Values are n (%).
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor block; ER = estrogen receptor; MET = metabolic equivalent; PR = progesterone receptor.
For variables collected at multiple time points, the data presented were collected at the time point most proximal and before breast cancer.
A history of hypertension was ascertained through any of the following: study measurement of blood pressure at clinic visits, self-report of hypertension diagnosis, or report of antihypertensive treatment